Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,963 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Open enrollment, early-phase tilt
Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.
- 275
- recruiting participants now
- 37%
- of trials open to enrollment
- 75
- in Phase 3-4 (later-stage)
- 53
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 12 of 15
Using Virtual Reality (VR) Models for Robotic Prostatectomy
Ceevra
NCT03943368
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
Massachusetts General Hospital
NCT02375776
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCIC Clinical Trials Group
NCT00258388
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT02218606
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
NCT00528866
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
Cell Genesys
NCT00140348
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
NCT00052845
Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
UNC Lineberger Comprehensive Cancer Center
NCT03156244
Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy
H. Lee Moffitt Cancer Center and Research Institute
NCT00042731
Reiki/Energy Healing in Prostate Cancer
The Cleveland Clinic
NCT00065208
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00348595
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
GTx
NCT01615120
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT01543659
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Ferring Pharmaceuticals
NCT01491971
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Ascenta Therapeutics
NCT00286793
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
NCT01429064
The "PC-LIGHT" Study
Northwestern University
NCT03419585
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Cancer Institute (NCI)
NCT02649855
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT02135653
Development of a Clinical Trial Specific Question Prompt List
Memorial Sloan Kettering Cancer Center
NCT00662324
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Weill Medical College of Cornell University
NCT03383107
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Cancer Institute (NCI)
NCT00450463
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
Alliance for Clinical Trials in Oncology
NCT00006214
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
NCT00006359
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT01630590
Cancer DNA Detection in Blood and Urine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02657863
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
University of Wisconsin, Madison
NCT00022412
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
Duke University
NCT00941915
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
NCT00181584
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
Eastern Cooperative Oncology Group
NCT00003871
Metformin Prostate Cancer Adjuvant Trial
NYU Langone Health
NCT02176161
AZD2171 to Treat Prostate Cancer
National Cancer Institute (NCI)
NCT00436956
Eating, Activity, and Stress Education
University of South Carolina
NCT01434004
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
University of Wisconsin, Madison
NCT01516866
Embr Thermal Device for Hot Flash Management in Prostate Cancer
Embr Labs
NCT04892914
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Kaiser Permanente
NCT00284752
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
Mayo Clinic
NCT02874014
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
NCT06604442
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
Weill Medical College of Cornell University
NCT00538668
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
Bayer
NCT00350051
The Specific Role of Isoflavones in Reducing Prostate Cancer Risk
H. Lee Moffitt Cancer Center and Research Institute
NCT00617617
Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy
Benaroya Research Institute
NCT04098809
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Clinton Bahler
NCT04936334
Dual-Tracer Theranostic PET
University of Utah
NCT05680675
Sleep, Exercise, Nutrition and Survivorship in Prostate Cancer
NYU Langone Health
NCT05318131
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
UConn Health
NCT00859027
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis
NCT02325557
Acupuncture Treatment for Hot Flashes Study
New York Presbyterian Brooklyn Methodist Hospital
NCT00421902
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Massachusetts General Hospital
NCT00147212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Prostate Cancer right now
275 recruiting of 749 indexed (37% open).
Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Prostate Cancer?
PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Prostate Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.